

CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAM

ANALYSIS OF 2016 FUNDING LEVELS

Congressionally Directed Medical Research Programs

CDMRP



Department of Defense

The Congressionally Directed Medical Research Program is an office within the US Army Medical Research and Materiel Command that administers competitive grant programs for certain medical research programs that are funded by Congress in the annual Department of Defense appropriation.

There are multiple changes for 2016 that you should be aware of. For additional details or questions about how McAllister & Quinn can help your organization compete for funding, contact:

Andy Quinn, Managing Partner
(202) 296-2741
andy@mcallisterquinn.com

Funding Increases in FY16

The **Autism Research Program** (ARP) is funded at \$7,500,000 for FY16, which represents a \$1,500,000 increase from the FY15 level. The mission of the ARP is to promote innovative research that advances the understanding of autism spectrum disorders and leads to improved outcomes.

The **Lung Cancer Research Program** (LCRP) is funded at \$12,000,000 for FY16, which represents a \$1,500,000 increase from the FY15 level. The mission of the LCRP is to support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer.

The **Multiple Sclerosis Research Program** (MSRP) is funded at \$6,000,000 for FY16, which represents a \$1,000,000 increase from the FY15 level. The mission of the MSRP is to prevent the occurrence of, cure, reverse, or slow the progression of, and lessen the personal and societal impact of multiple sclerosis.

The **Peer Reviewed Alzheimer Research Program** (PRARP) is funded at \$15,000,000 for FY16, a \$3,000,000 increase from the FY15 level. The mission of the PRARP is to understand the association between traumatic brain injury (TBI) and Alzheimer's disease (AD) and to reduce the burden on affected individuals and caregivers, especially in the military and Veteran communities.

The **Peer Reviewed Medical Research Program** (PRMRP) is funded at \$278,700,000 for FY16, which represents a \$31,200,000 increase from the FY15 level. The FY16 PRMRP will solicit research applications for the following 39 topics areas:

- Acute Lung Injury
- Antimicrobial Resistance
- Chronic Migraine and Post-Traumatic Headaches
- Congenital Heart Disease
- Constrictive Bronchiolitis
- Diabetes
- Dystonia
- Emerging Infectious Diseases
- Focal Segmental Glomerulosclerosis
- Fragile X Syndrome
- Hepatitis B
- Hereditary Angioedema
- Hydrocephalus
- Inflammatory Bowel Disease
- Influenza
- Integrative Medicine
- Interstitial Cystitis
- Lupus
- Malaria
- Metals Toxicology
- Mitochondrial Disease
- Nanomaterials for Bone Regeneration
- Nonopioid Pain Management
- Pancreatitis
- Pathogen-Inactivated Dried Plasma
- Polycystic Kidney Disease
- Post-Traumatic Osteoarthritis
- Psychotropic Medications
- Pulmonary Fibrosis
- Respiratory Health
- Rett Syndrome
- Rheumatoid Arthritis
- Scleroderma
- Sleep Disorders
- Tinnitus
- Tuberculosis
- Vaccine Development for Infectious Disease
- Vascular Malformations
- Women's Heart Disease

- **New Topic Areas in FY16:** Antimicrobial resistance, constrictive bronchiolitis, emerging infectious diseases, food allergies, influenza, nonopioid pain management, Rett syndrome, tuberculosis, and vaccine development for infectious disease.

- **FY15 Topic Areas Eliminated in FY16:** Acupuncture, advanced prosthetics, arthritis, burn pit exposure, cardiovascular health, dengue, DNA vaccine technology for postexposure prophylaxis, healthcare-acquired infection reduction, and osteoarthritis.

The **Trauma Clinical Research Program** is funded at \$10,000,000 for FY16, which represents a \$10,000,000 increase from the FY15 level.

Funding Decreases in FY16

The **Bone Marrow Failure Research Program** (BMFRP) is funded at \$3,000,000 for FY16, which represents a \$200,000 decrease from the FY15 level. In FY16, the BMFRP will support innovative ideas and high-impact approaches based on scientifically sound evidence in order to move toward the vision to understand and cure BMF.

The **Reconstructive Transplant Research Program** (RTR) is funded at \$12,000,000 for FY16, which represents a \$3,000,000 decrease from the FY15 level. The mission of the RTR is to deliver innovative solutions in the field of vascularized composite allotransplantation to restore form, function, and appearance to those who have been catastrophically injured.

New Programs in FY16

The **Tick-Borne Disease Research Program** is funded at \$5,000,000 for FY16.

Consistent Funding in FY16

The **Alcohol and Substance Abuse Disorders Research Program** (ASADRP) is funded at \$4,000,000 for FY16, which is consistent with the FY15 level. The mission of the ASADRP is to explore new opportunities to address alcohol and substance abuse disorders, especially related to TBI and post-traumatic stress disorder (PTSD), through multidisciplinary, team-based research efforts that translate basic knowledge into enhanced clinical protocols.

The **Amyotrophic Lateral Sclerosis Research Program** (ALSRP) is funded at \$7,500,000 for FY16, which is consistent with the FY15 level. In FY16, the ALSRP program will support post-discovery, preclinical development of therapeutics for ALS; and hypothesis-driven drug discovery efforts focused on ALS therapeutics.

The **Breast Cancer Research Program** (BCRP) is funded at \$120,000,000 for FY16, which is consistent with the FY15 level. The mission of the BCRP is to end breast cancer by funding innovative, high-impact research through a partnership of scientists and consumers.

The **Duchenne Muscular Dystrophy Research Program** (DMDRP) is funded at \$3,200,000 for FY16, which is consistent with the FY15 level. The mission of the DMDRP is to support research to accelerate the development and clinical testing of new therapeutics and increase our understanding of successes and failures of therapeutics in clinical trials.

The ***Epilepsy Research Program*** (ERP) is funded at \$7,500,000 for FY16, which is consistent with the FY15 level. The mission of the ERP is to fund research to understand the magnitude and the underlying mechanisms of post-traumatic epilepsy, especially in Service members and Veterans.

The ***Gulf War Illness Research Program*** (GWIRP) is funded at \$20,000,000 for FY16, which is consistent with the FY15 level. The mission of the GWIRP is to fund innovative Gulf War Illness research to identify effective treatments, improve definition and diagnosis, and better understand pathobiology and symptoms.

The ***Joint Warfighter Medical Research Program*** (JWMRP) is funded at \$50,000,000 for FY16, which is consistent with the FY15 level. The mission of the JWMRP is to accelerate research and development projects that have the potential to close high priority Department of Defense medical capability gaps.

The ***Military Burn Research Program*** (MBRP) is funded at \$8,000,000 in FY16, which is consistent with the FY15 level. The mission of the MBRP is to identify and address the traumas of burn, especially those combat-related injuries that affect the military population.

The ***Neurofibromatosis Research Program*** (NFRP) is funded at \$15,000,000 for FY16, which is consistent with the FY15 level. In FY16, the NFRP will support:

- Health services research
 - Evidence-based clinical care pathways
 - Innovative healthcare delivery systems
 - Utilization of technology and informatics
- Heterogeneity of neurofibromas and other NF-related tumors
- Non-tumor manifestations
 - Sleep, pain, hypotonia, etc. including quality of life measures, self-reported and otherwise
- Novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics or similar approaches
 - Transition from benign to malignant
- Nutritional, environmental, and other modifiers of NF
- Post-adolescent manifestations
- Preclinical efficacy studies
- Target identification, drug discovery, targeted and immunotherapies

The ***Neurotoxin Exposure Treatment Parkinson's Research Program*** (NETPR) is funded at \$16,000,000 for FY16, which is consistent with the FY15 level. The overall goals of the NETPR are to develop means to correlate risk factors and dysfunction associated with Parkinson's disease (PD); develop means to identify risk factors for subsets of the affected population; correlate clinical phenotype and molecular underpinning; and develop candidate therapeutics, based on identified molecular pathway intervention points, to halt progression and extend quality of life for the at-risk population.

The ***Orthotics and Prosthetics Outcomes Research Program*** (OPORP) is funded at \$10,000,000 for FY16, which is consistent with the FY15 level. The goal of the OPORP is to improve our understanding and ultimately advance the implementation of the most effective prescriptions for prosthetic and orthotic devices, treatment, rehabilitation, and secondary health effect prevention options for patients, clinicians, other caregivers, and policymakers.

The ***Ovarian Cancer Research Program*** (OCRP) is funded at \$20,000,000 for FY16, which is consistent with the FY15 level. In FY16, supported efforts will include:

- The translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life
- Meritorious basic and clinically oriented research in ovarian cancer
- The addition of new Early-Career Investigators to the unique, interactive virtual academy that will provide intensive mentoring, national networking, and a peer group for junior faculty
- Innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward

The ***Peer Reviewed Cancer Research Program*** (PRCRP) is funded at \$50,000,000 for FY16, which is consistent with the FY15 level. In FY16, the PRCRP is directed to support research in the following areas:

- Bladder cancer
- Colorectal cancer
- Immunotherapy
- Kidney cancer
- Listeria vaccine for cancer
- Liver cancer
- Lymphoma
- Melanoma and other skin cancers
- Mesothelioma
- Neuroblastoma
- Pancreatic cancer
- Pediatric brain tumors
- Stomach cancer

The ***Peer Reviewed Orthopedic Research Program*** (PRORP) is funded at \$30,000,000 for FY16, which is consistent with the FY15 level. The mission of the PRORP is to address the most significant gaps in care for the leading burden of injury and loss of fitness for military duty by funding innovative, high-impact, clinically relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries sustained during combat or combat-related activities.

The ***Prostate Cancer Research Program*** (PCRP) is funded at \$80,000,000 for FY16, which is consistent with the FY15 level. The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease.

The ***Psychological Health/Traumatic Brain Injury Research Program*** (PH/TBIRP) is funded at \$125,000,000 which is consistent with the FY15 level. The mission of the PH/TBIRP is to establish, fund, and integrate both individuals and multi-agency research efforts that will lead to improved prevention, detection, and treatment of PH and TBI.

The *Spinal Cord Injury Research Program* (SCIRP) is funded at \$30,000,000 for FY16, which is consistent with the FY15 level. The mission of the SCIRP is to fund research and foster collaborative environments for the development and translation of more effective strategies to improve the health and well-being of Service members, Veterans, and other individuals with SCI.

The *Tuberous Sclerosis Complex Research Program* (TSCRCP) is funded at \$6,000,000 for FY16, which is consistent with the FY15 level. The goal of the FY16 TSCRCP is to encourage innovative research aimed at understanding the pathogenesis, and preventing and treating the manifestations of TSC. Within this context, the FY16 TSCRCP encourages applications that address the critical needs of the TSC community in one or more of the following FY16 Focus Areas:

- Understanding phenotypic heterogeneity in TSC
- Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency
- Improving TSC disease models
- Developing clinical biomarkers for TSC
- Facilitating therapeutics and clinical trials research

The *Vision Research Program* (VRP) is funded at \$10,000,000 for FY16, which is consistent with the FY15 level. The vision of the VRP is to improve the care of military personnel affected by eye injuries and diseases by identifying clinical needs and addressing them through directed medical research efforts.

Additional CDMRP Programs

The *Defense Medical Research and Development Program* (DMRDP) funding levels for FY16 are to be determined. The FY15 level was \$130,900,000. The mission of the DMRDP is to provide full life-cycle operational execution management for Defense Health Program core research program areas in support of advancing collaborative, innovative medical research and development to improve military community health and save lives on and off the battlefield.

Summary of Funding Levels

<i>Research Program</i>	<i>FY15 Enacted (USD, millions)</i>	<i>FY16 Final Bill (USD, millions)</i>
<i>Alcohol and Substance Abuse</i>	\$4.0	\$4.0
<i>Amyotrophic Lateral Sclerosis</i>	\$7.5	\$7.5
<i>Autism</i>	\$6.0	\$7.5
<i>Bone Marrow Failure</i>	\$3.2	\$3.0
<i>Breast Cancer</i>	\$120.0	\$120.0
<i>Duchenne Muscular Dystrophy</i>	\$3.2	\$3.2
<i>Defense Medical Research and Development</i>	\$130.9	TBD
<i>Epilepsy</i>	\$7.5	\$7.5
<i>Gulf War Illness</i>	\$20.0	\$20.0
<i>Joint Warfighter Medical</i>	\$50.0	\$50.0
<i>Lung Cancer</i>	\$10.5	\$12.0
<i>Military Burn</i>	\$8.0	\$8.0
<i>Multiple Sclerosis</i>	\$5.0	\$6.0
<i>Neurofibromatosis</i>	\$15.0	\$15.0
<i>Neurotoxin Exposure Treatment Parkinson's</i>	\$16.0	\$16.0
<i>Orthotics and Prosthetics Outcomes</i>	\$10.0	\$10.0
<i>Ovarian Cancer</i>	\$20.0	\$20.0
<i>Peer Reviewed Alzheimer's</i>	\$12.0	\$15.0
<i>Peer Reviewed Cancer</i>	\$50.0	\$50.0
<i>Peer Reviewed Medical</i>	\$247.5	\$278.7
<i>Peer Reviewed Orthopaedic</i>	\$30.0	\$30.0
<i>Prostate Cancer</i>	\$80.0	\$80.0
<i>Psychological Health/Traumatic Brain Injury</i>	\$125.0	\$125.0
<i>Reconstructive Transplant Research</i>	\$15.0	\$12.0
<i>Spinal Cord Injury</i>	\$30.0	\$30.0
<i>Tick-Borne Disease Research</i>	\$0	\$5.0
<i>Trauma Clinical</i>	\$0	\$10.0
<i>Tuberous Sclerosis Complex</i>	\$6.0	\$6.0
<i>Vision</i>	\$10.0	\$10.0

About McAllister & Quinn

McAllister & Quinn provides clients with comprehensive, personalized services to help them execute and exceed their short- and long-term strategic priorities. McAllister & Quinn is recognized as a field leader and has a proven track record of delivering tangible results for clients.